Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.
about
Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressureLong-term captopril therapy in severe refractory congestive heart failureCaptopril in renovascular hypertension: long-term use in predicting surgical outcome.Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation.Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.Enalapril: a long-acting angiotensin-converting enzyme inhibitor.Pharmacology of converting enzyme inhibitors.Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.Effects of captopril in animal models of hypertension.Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium.Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibitionEffect of captopril on renal function in patients with congestive heart failure.Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure.Pituitary - adrenocortical function in patients during treatment with the angiotensin-converting enzyme inhibitor captopril.The effects of cilazapril alone and in combination with frusemide in healthy subjects.Renal and pulmonary effects of angiotensin converting enzyme inhibition in chronic hypoxic lung disease.The causal role of salt depletion in acute renal failure due to captopril in hypertensive patients with a single functioning kidney and renal artery stenosis.Antihypertensive effects of the novel converting-enzyme inhibitor YS 980 in spontaneously hypertensive rats.Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.Synergism of CE-inhibition and diuresis. A study with ramipril, piretanide and HCT in SHR.Renal tubular peptide catabolism in chronic vascular rejection.Clinical factors associated with hyperkalemia in patients with congestive heart failure.Implications of antihypertensive therapy on sodium balance and sodium and water retention.The effect of captopril on renal hemodynamics in hypertensive patients.Captopril in treatment-resistant essential and renal hypertension.
P2860
Q28367116-BB9074DB-7085-4007-A767-090E41C22503Q34142036-C2099A3D-540F-4E92-B6F1-B26D32CBC248Q34449903-B431B1E5-C25E-4927-90C2-77A1B9746A25Q34511334-C9E40460-E3A1-45A0-B64F-6F76927F8683Q34750266-B3E57367-631F-4E5C-A22C-B6D2909334E2Q34753785-D09F77F6-9E1B-4FB6-945D-6C3BDE686F39Q35609741-2DAF82D4-C58F-4B7B-95D1-53621CC9819CQ36854757-8C5737E1-5406-49B4-AC07-A6D613C05BB6Q37318279-C732AB6F-AC90-404D-A136-17301D756F18Q38031524-DC82F933-C688-443A-BD16-36ACAADB5190Q39177686-C767A4F4-CABE-4FA9-9A37-84A673FA2915Q39510432-336BE04E-F2B0-4448-97B6-9E8951911DBFQ40138907-9F039041-E47A-42D7-B446-B91AAB7360A8Q40292890-40857518-9CD2-42B3-9D6E-817FC7BE6C7EQ40526165-A772E1DC-3476-4921-A8AA-B7E9452A465EQ41318569-5F714F4E-A96E-43BD-A222-F198257623B7Q41322685-AC4435C6-BCD1-4E55-A864-9B19D264D6F0Q41375013-FFE440DC-D856-4E84-823C-F6D05E367DF9Q41552436-34D70FA1-9A5E-46ED-82C2-E4299B71FEFCQ41923690-4AD6E98A-CEB5-451C-925A-B5276716E90FQ42126481-0A4431F7-217C-44CC-8D3F-7B14BC29A46AQ42217442-78592DD7-239E-47AC-BC5B-2750862BFA87Q42244973-86D61965-9B38-4FC1-A717-B75FEA8A942AQ43222299-ABA41393-0B98-4C4D-8EA9-B3F6924EA15EQ43666981-4928A507-EEAF-4133-AF7D-E79B0D66DA4EQ43703531-78A8EBDE-473B-467D-9FDE-D427740C30D5Q46492458-31B23A44-C823-4121-9D59-05B7C772C714Q46519171-DF613CA0-BF28-4C27-8371-3BB937FDD651Q54470987-87763195-5E4A-42A4-B693-EF899CB495C4Q54525522-9C068FE6-50F9-45EA-8FFF-773F521CB1EA
P2860
Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Interruption of the renin-angi ...... ium retention and natruiresis.
@en
type
label
Interruption of the renin-angi ...... ium retention and natruiresis.
@en
prefLabel
Interruption of the renin-angi ...... ium retention and natruiresis.
@en
P2093
P356
P1433
P1476
Interruption of the renin-angi ...... ium retention and natruiresis.
@en
P2093
D N McKinstry
J E Sealey
J H Laragh
P304
P356
10.1161/01.HYP.1.3.274
P407
P577
1979-05-01T00:00:00Z